Research progress of the relationship between phenylacetylglutamine and cardiovas-cular disease
10.20039/j.cnki.1007-3949.2025.02.012
- VernacularTitle:苯乙酰谷氨酰胺与心血管疾病的关系研究进展
- Author:
Wan CHEN
1
;
Xiaohua YU
;
Jin ZOU
;
Gang WANG
Author Information
1. 南华大学附属第一医院心血管内科,湖南省衡阳市 421001
- Publication Type:Journal Article
- Keywords:
phenylacetylglutamine;
cardiovascular disease;
gut microbiota;
atherosclerosis
- From:
Chinese Journal of Arteriosclerosis
2025;33(2):178-184
- CountryChina
- Language:Chinese
-
Abstract:
Cardiovascular diseases have become the leading cause of mortality worldwide.The gut microbiota and its metabolites play an important role in the occurrence and development of cardiovascular diseases,and an imbalance of gut microbiota and its metabolites can promote the progression of cardiovascular diseases.Phenylacetylglutamine is a phenyl-alanine metabolite of intestinal flora.More and more studies have shown that phenylacetylglutamine is an independent risk factor of cardiovascular diseases and a potential biomarker of cardiovascular diseases.It is involved in the pathogenesis of cardiovascular diseases,such as arrhythmia,heart failure,atherosclerosis,etc.Therefore,interventions targeting pheny-lacetylglutamine are expected to become a new strategy for treating cardiovascular diseases.This review focuses on the role of phenylacetylglutamine in the occurrence and development of several common cardiovascular diseases.
